Скачать или смотреть OncoSil Medical (ASX:OSL): Completes patient recruitment for the TRIPP-FFX clinical trial.

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has successfully completed patient recruitment for the TRIPP-FFX clinical trial.

🔬 This study represents an important part of OncoSil Medical’s well-articulated clinical development strategy.
🧪 The primary objective of the TRIPP-FFX trial is to evaluate the safety and efficacy of the OncoSil™ device when used in addition to FOLFIRINOX chemotherapy.
📅 OncoSil Medical expects data from the TRIPP-FFX study to become available in early calendar 2026.

“The TRIPP-FFX study represents an important step in exploring new therapeutic options for patients with locally advanced pancreatic cancer. The integration of the OncoSil™ device with FOLFIRINOX chemotherapy could offer a meaningful improvement in clinical outcomes. We are pleased to have completed recruitment and look forward to analysing the results.” Giuseppe Malleo, One of the two Coordinating Investigators of the TRIPP-FFX study and Associate Professor of Surgery at the University of Verona

"We are thrilled by the speed at which patient recruitment for the TRIPP-FFX clinical trial has occurred. It means that yet another milestone in our well-articulated clinical development strategy for the OncoSil™ device has been met. I personally want to thank our clinical partners for their sustained efforts to deliver the study’s target patient recruitment level. Because of their hard work and dedication, the strong momentum behind OncoSil Medical team’s commitment to demonstrate the multiple ways its innovative treatment platform will continue to occur at a rapid pace." Nigel Lange, CEO & Managing Director of OncoSil Medical

ASX announcement ⚡ https://cdn-api.markitdigital.com/api...